The Ministry of Health of Russia issued permission to conduct phase I and II clinical trials of the Epivakkorona-N coronavirus vaccine of center Vector. This is evidenced by the data of the state register of permits for research of the ministry.
Volunteers between the ages of 18 and 60 will take part in the tests.
Research started on April 8, 2021, and will stop in September 30, 2021,” the message is clarified on the State Register of Medicines (SRM) website.
“EpiVacCorona-H” is a vaccine based on peptide antigens, according to registry data.
